Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
29 8월 2023 - 5:00AM
Business Wire
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage
biopharmaceutical company focused on developing and commercializing
novel therapies for rare endocrine disorders with significant unmet
medical need, today announced that Javier Szwarcberg, M.D., M.P.H.,
Chief Executive Officer, will present at the H.C. Wainwright 25th
Annual Global Investment Conference on September 12, 2023, at 3:30
p.m. ET.
Interested parties can access the live webcast here. An archived
copy of the webcast will be available on the events section of the
company’s investor relations website for approximately 30 days.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company
focused on developing and commercializing novel therapies for rare
endocrine disorders with significant unmet medical need. Spruce is
initially developing its wholly-owned product candidate,
tildacerfont, as the potential first non-steroidal therapy for
patients suffering from classic congenital adrenal hyperplasia
(CAH). Spruce is also developing tildacerfont for women suffering
from polycystic ovary syndrome (PCOS). To learn more, visit
www.sprucebio.com and follow us on Twitter/X @Spruce_Bio, LinkedIn,
Facebook and YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230828696222/en/
Media Contact Will Zasadny Evoke Canale (619) 961-8848
will.zasadny@evokegroup.com media@sprucebio.com
Investors Samir Gharib President and CFO Spruce
Biosciences investors@sprucebio.com
Spruce Biosciences (NASDAQ:SPRB)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Spruce Biosciences (NASDAQ:SPRB)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
